scholarly journals Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies

2017 ◽  
Vol 92 (12) ◽  
pp. 1349-1355 ◽  
Author(s):  
Raffaella Origa ◽  
Maria Laura Ponti ◽  
Aldo Filosa ◽  
Alfonso Galeota Lanza ◽  
Antonio Piga ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Antiviral Drugs ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Direct Acting

DI-074 Evaluation of the treatment response with the new direct acting antiviral drugs for the treatment of hepatitis C virus infection in cirrhotic patients

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A151.1-A151
Author(s):  
MA Parro Martín ◽  
MA Rodríguez Sagrado ◽  
MR Pintor Recuenco ◽  
N Vicente Oliveros ◽  
M Vélez-Díaz-Pallarés ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Treatment Response ◽  
Antiviral Drugs ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Cirrhotic Patients ◽  
Direct Acting

Tratamiento de hepatitis crónica por virus de Hepatitis C con drogas antivirales de acción directa en un paciente con fibrosis quística

2021 ◽  
Vol 51 (1) ◽  
Author(s):  
José Daniel Bosia ◽  
María Virginia D´Ascenzo ◽  
Silvia Mabel Borzi ◽  
Ezequiel Barán ◽  
María Cecilia Calzona
Keyword(s):  
Cystic Fibrosis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Sustained Viral Response ◽  
Antiviral Drugs ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Pegylated Interferon Plus Ribavirin ◽  
Direct Acting

The development of new direct acting antiviral drugs for the treatment of Hepatitis C virus infection, has made it possible to obtain an excellent cure rate and extend the indications for eradication of Hepatitis C virus to previously very difficult populations to treat like cystic fibrosis, in whom treatment with classic regimens based on pegylated Interferon plus ribavirin could favor worsening lung function. We present a case of a 41-year-old man with cystic fibrosis, diagnosed with Hepatitis C virus infection, genotype 1a, non-cirrhotic, treated with direct acting antiviral drugs for twelve weeks, obtaining a sustained viral response, without adverse effects. One year later, being on the waiting list, underwent a bipulmonary transplant.

Efficacy of Direct-Acting Antiviral Combination Therapy in the Treat-ment of Hepatitis C Virus Among Kidney Transplant Patients

2020 ◽  
Vol 18 ◽  
Author(s):  
Mohammed Al Atbee ◽  
Saad Shaheen Al-Taher ◽  
Majid Alabbood
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Kidney Transplant ◽  
Virological Response ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antiviral ◽  
Transplant Patients ◽  
Kidney Transplant Patients ◽  
Direct Acting

Background: Up to date, there is no consensus on the best combination of direct-acting antiviral to treat hepatitis C virus in kidney transplant recipients. Objective: This study aims to analyze the efficacy of combination of sofosbuvir and ledipasvir regimen for treatment of hepatitis C virus infected kidney transplant patients. Method: A cross-sectional study conducted in a nephrology clinic and the Nephrology Center in Basrah Teaching Hospital from June 2015 to June 2018. Ledifos (90 mg Ledipasvir and 400 mg Sofosbuvir fixed-dose) was given as a single daily dose for all the participants for 12 weeks. Response for therapy was tested by follow up hepatitis C virus load at the end of 12 weeks and 24 weeks. The sustained virological response was defined as negative viral load of hepatitis C virus (aviremia) at the end of therapy. This study was done according to the Helsinki Congress. Results: A total of 60 (16 females) patients with renal transplantation and hepatitis C virus infection were included. Mean age was 40±6.2 years. A sustained virological response observed in all of the patients who received Ledifos after 12 and 24 weeks of therapy for all genotypes (1a, 1b and 4); p= 0.0001. Genotype 1a was more prevalent among males, 34 (56.6%); p= 0.0001, and it was the most common genotype tested negative serologically, 11 (18.3%). Conclusion: Ledifos therapy is effective and safe option for the treatment of hepatitis C virus infection in the post–renal transplant setting.

Sign in / Sign up

Export Citation Format

Share Document